Clinical Trial Update: Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease

View source ↗

Summary

A completed clinical trial assessing the risk of nephrogenic systemic fibrosis after MultiHance (gadoteridol) administration in patients with chronic kidney dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Nephrogenic Systemic Fibrosis

Drugs mentioned

• MULTIHANCE (Gadobenate dimeglumine)

Snippet

Sponsor: Bracco Diagnostics, Inc | Conditions: Renal Insufficiency | Status: COMPLETED